Watson Launches Generic Zyban
This article was originally published in The Pink Sheet Daily
Watson launched its "authorized" generic of GlaxoSmithKline's Zyban (bupropion 150 mg) on May 28
You may also be interested in...
Andrx will share in the profits of Impax/Teva’s bupropion 150 mg for smoking cessation for six months. Relinquishment of first-to-file rights mirrors Andrx’ earlier decision to give up exclusivity on Wellbutrin SR.
Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.
Agency’s clinical experts favor granting access under regulations intended for investigational drugs but ‘lawyers want consistency under the law,’ FDA’s Woodcock says; use of the expanded access pathway for approved agents is generally unnecessary but may provide sponsors with some regulatory cover, external experts say.